HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.
about
An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challengeA single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.Prospects and perspectives for development of a vaccine against herpes simplex virus infections.Evasion of early antiviral responses by herpes simplex viruses.A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancyHerpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Vaccination against infectious diseases: what is promising?A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus.The Pseudorabies Virus Glycoprotein gE/gI Complex Suppresses Type I Interferon Production by Plasmacytoid Dendritic Cells.A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells.Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.Applications of gold nanoparticles in virus detection.Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis
P2860
Q33916162-7F4588A4-4EE8-409A-BECC-F7637FB192EDQ34414463-16860A8C-0084-4DD8-9D64-8483F7D08043Q34431547-63046105-94BF-4EDD-B815-31418E8E82D8Q35414669-4CF51622-ED1D-420E-BC39-0FA030AFD778Q36381485-40385539-FF74-43BD-8FA9-3A404E60DA81Q36824210-9D485970-F6F8-44C6-9537-3966446C20B6Q38234231-CF90369D-C0FF-4A9A-94B4-CEA30A0B8E31Q38353693-7C4294BE-58B8-4CEA-B77D-A22F1DDDA9B6Q38998935-A9F107AB-31CB-4764-A3EE-A3C343DE8D33Q40067153-79EE67FF-E675-488F-8172-CC3CBC7BDD6FQ40443062-9156171A-C8FB-4220-9C32-0968FF490E76Q52647635-60A0217C-9093-455B-A6B2-1B5B2236C5DBQ58692099-883C9EE3-F287-4313-8581-E27A13A0664C
P2860
HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HSV-2 vaccine: current status ...... veloping an efficient vaccine.
@en
HSV-2 vaccine: current status ...... veloping an efficient vaccine.
@nl
type
label
HSV-2 vaccine: current status ...... veloping an efficient vaccine.
@en
HSV-2 vaccine: current status ...... veloping an efficient vaccine.
@nl
prefLabel
HSV-2 vaccine: current status ...... veloping an efficient vaccine.
@en
HSV-2 vaccine: current status ...... veloping an efficient vaccine.
@nl
P2093
P2860
P356
P1433
P1476
HSV-2 vaccine: current status ...... veloping an efficient vaccine.
@en
P2093
Jian-Guang Wang
Shi-Kun Guo
Xiao-Peng Zhu
Zaka S Muhammad
P2860
P304
P356
10.3390/V6020371
P577
2014-01-24T00:00:00Z